Accustomed Chaos » Celiac News » Phase II Grant Awarded to Research “Low Gluten Wheat”
Phase II Grant Awarded to Research “Low Gluten Wheat”
Arcadia Biosciences Inc. is a agricultural technology focused company in California, USA that look at ways to benefit health and environment. Arcadia had received the Small Business Technology Transfer Program (STTR) grant from the National Institutes of Health partnering with Washington State University (WSU) in 2005 to research lines of wheat with reduced celiac disease-causing proteins.
Working with Dr. von Wettstein and his colleagues at WSU, Arcadia used TILLING® technology to identify wheat plants in which harmful gluten proteins are minimized.
The progress under our Phase I grant has made us increasingly optimistic about our ability to deliver wheat varieties that people with celiac disease can enjoy. If the approach we are exploring in the Phase II grant is successful, our new wheat varieties may also appeal to a much broader market.
A Phase II grant has just been awarded totaling $855,500 funded by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) and the American Recovery and Reinvestment Act (ARRA). The purpose of this grant will seek to reduce and remove a far broader range of the gluten containing proteins while still maintaining enough for ‘bread-making qualities’. Phase II research is expected to be completed in mid-2011.